Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PET… Read more
Sprint Bioscience AB (SPRINT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -2.290x
Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has a cash flow conversion efficiency ratio of -2.290x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-13.89 Million) by net assets (Skr6.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sprint Bioscience AB - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Sprint Bioscience AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sprint Bioscience AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sprint Bioscience AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Consumer Public Company Limited
BK:GLOCON
|
-0.014x |
|
Youil Energy Technology Co. Ltd.
KQ:340930
|
0.132x |
|
Eureka Homestead Bancorp Inc
PINK:ERKH
|
0.004x |
|
EVZ Ltd
AU:EVZ
|
0.269x |
|
Brainzcompany Co. Ltd.
KQ:099390
|
0.011x |
|
Iep Invest
BR:IEP
|
-0.003x |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
0.007x |
|
Lulu's Fashion Lounge Holdings Inc
NASDAQ:LVLU
|
-0.722x |
Annual Cash Flow Conversion Efficiency for Sprint Bioscience AB (2012–2024)
The table below shows the annual cash flow conversion efficiency of Sprint Bioscience AB from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr9.27 Million | Skr-23.36 Million | -2.519x | -405.90% |
| 2023-12-31 | Skr27.77 Million | Skr22.87 Million | 0.823x | +139.31% |
| 2022-12-31 | Skr28.19 Million | Skr-59.05 Million | -2.095x | -267.93% |
| 2021-12-31 | Skr70.45 Million | Skr-40.12 Million | -0.569x | +83.84% |
| 2020-12-31 | Skr9.14 Million | Skr-32.22 Million | -3.524x | -38.64% |
| 2019-12-31 | Skr11.02 Million | Skr-28.00 Million | -2.542x | -396.07% |
| 2018-12-31 | Skr37.24 Million | Skr-19.08 Million | -0.512x | +37.56% |
| 2017-12-31 | Skr28.09 Million | Skr-23.05 Million | -0.821x | -394.71% |
| 2016-12-31 | Skr28.49 Million | Skr7.93 Million | 0.278x | +61.03% |
| 2015-12-31 | Skr4.82 Million | Skr833.54K | 0.173x | +132.66% |
| 2014-12-31 | Skr20.32 Million | Skr-10.76 Million | -0.529x | +50.07% |
| 2013-12-31 | Skr3.36 Million | Skr-3.57 Million | -1.060x | +49.25% |
| 2012-12-31 | Skr1.10 Million | Skr-2.29 Million | -2.089x | -- |